Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Leases (2019 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Current Leases for 7 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 347.65% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 347.65% year-over-year, with the annual reading at $2.3 million for FY2025, 347.65% up from the prior year.
  • Current Leases hit $2.3 million in Q4 2025 for Protagonist Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.6 million in Q1 2023 to a low of $45000.0 in Q3 2024.
  • Historically, Current Leases has averaged $1.8 million across 5 years, with a median of $2.2 million in 2025.
  • Biggest five-year swings in Current Leases: plummeted 97.5% in 2024 and later soared 4851.11% in 2025.
  • Year by year, Current Leases stood at $2.2 million in 2021, then increased by 14.32% to $2.5 million in 2022, then crashed by 54.63% to $1.1 million in 2023, then crashed by 55.3% to $510000.0 in 2024, then surged by 347.65% to $2.3 million in 2025.
  • Business Quant data shows Current Leases for PTGX at $2.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.2 million in Q2 2025.